DGX · Categories · Downgrades
DGX - Analyst downgrades
Quest Diagnostics Incorporated (DGX) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for DGX
- Quest Diagnostics downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00
- Quest Diagnostics downgraded by Citigroup with a new price targetCitigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00
- Quest Diagnostics downgraded by BofA Securities with a new price targetBofA Securities downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $148.00 from $166.00 previously
- Quest Diagnostics downgraded by Citigroup with a new price targetCitigroup downgraded Quest Diagnostics from Neutral to Sell and set a new price target of $125.00 from $145.00 previously
- Quest Diagnostics downgraded by Citigroup with a new price targetCitigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $140.00 from $175.00 previously
- Quest Diagnostics downgraded by UBS with a new price targetUBS downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $139.00 from $160.00 previously
- Quest Diagnostics downgraded by Jefferies with a new price targetJefferies downgraded Quest Diagnostics from Buy to Hold and set a new price target of $135.00
- Quest Diagnostics downgraded by Deutsche Bank with a new price targetDeutsche Bank downgraded Quest Diagnostics from Buy to Hold and set a new price target of $129.00 from $190.00 previously
- Quest Diagnostics downgraded by Baird with a new price targetBaird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $137.00
- Quest Diagnostics downgraded by Robert W. BairdRobert W. Baird downgraded Quest Diagnostics from Outperform to Neutral
- Quest Diagnostics downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $137.00